<DOC>
	<DOCNO>NCT01769066</DOCNO>
	<brief_summary>The aim study explore Clinical Value Sequential Gefitinib With Pemetrexed/Platinum compare Pemetrexed/Platinum Advanced NSCLC .</brief_summary>
	<brief_title>Clinical Value Sequential Gefitinib With Pemetrexed/Platinum Advanced NSCLC</brief_title>
	<detailed_description>Patients randomize 2 group</detailed_description>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . 18~70 year 2 . Patients diagnose histologic , cytologic diagnosis IIIbIV nonsmall cell lung cancer 3 . Presence least one index lesion measurable CT scan MRI 4 . Ecog01 5 . Expected life time longer 12 week 6 . Normal laboratory value : leucocyte ≥ 4×109/L neutrophil ≥ 1.5×109/L platelet ≥ 100×109/L Hemoglobin ≥ 10g/L ALT AST ≤ 2.5×ULN ( ≤ 5×ULN liver metastasis ) 7 . Signed write informed consent Patients use drug accord protocol Patients allergic pemetrexed cisplatin Patients receive radiotherapy biological treatment 4 week trial Uncontrolled hydrothorax hydropericardium neuropathy toxicity ≥ CTC 3 Severe symptomatic heart disease Active upper gastrointestinal ulcer digestive disfunction Severe infection metabolic disfunction Patients malignant tumor Uncontrolled brain metastasis Patients accept clinical trial Female patient pregnant lactation period , patient without contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>